Cochrane · systematic review · CD004523
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
Wells, GA, Hsieh, S-C, Zheng, C, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 25%Low 6 · 50%Moderate 2 · 16.7%High 1 · 8.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Risedronate 5 mg/day compared to placebo for the primary prevention of osteoporotic fractures in postmenopausal women
Population: postmenopausal women at lower risk of fractures1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical vertebral fractures Risedronate 5 mg/day vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision, inconsistency |
Non‐vertebral fractures Risedronate 5 mg/day vs placebo | RR 0.54 [0.22, 1.35] | NR | Very low Downgraded: risk of bias, imprecision, inconsistency |
Hip fractures Risedronate 5 mg/day vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision, inconsistency |
Wrist fractures Risedronate 5 mg/day vs placebo | RR 0.48 [0.03, 7.5] | NR | Low Downgraded: risk of bias, imprecision, inconsistency |
Withdrawals due to adverse events Risedronate 5 mg/day vs placebo | RR 0.67 [0.38, 1.18] | NR | Low Downgraded: risk of bias, imprecision, inconsistency |
Serious adverse events Risedronate 5 mg/day vs placebo | RR 0.74 [0.42, 1.3] | NR | Very low Downgraded: risk of bias, imprecision, inconsistency |
Risedronate 5 mg/day compared to placebo for the secondary prevention of osteoporotic fractures in postmenopausal women
Population: pPostmenopausal women at higher risk of fractures1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical vertebral fractures Risedronate 5 mg/day vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision, indirectness |
Non‐vertebral fractures Risedronate 5 mg/day vs placebo | RR 0.8 [0.72, 0.9] | NR | Moderate Downgraded: risk of bias, imprecision, indirectness |
Hip fractures Risedronate 5 mg/day vs placebo | RR 0.73 [0.56, 0.94] | NR | Low Downgraded: risk of bias, imprecision, indirectness |
Wrist fractures Risedronate 5 mg/day vs placebo | RR 0.64 [0.33, 1.24] | NR | Very low Downgraded: risk of bias, imprecision, indirectness |
Withdrawals due to adverse events Risedronate 5 mg/day vs placebo | RR 0.98 [0.9, 1.07] | NR | High |
Serious adverse events Risedronate 5 mg/day vs placebo | RR 1 [0.94, 1.07] | NR | Moderate Downgraded: risk of bias, imprecision, indirectness |